Interim data from clinical trials can significantly impact biotech companies' stock prices. Positive results often lead to increased investor confidence and can drive the stock price up. Given the specificity of the trial (Phase 2, non-metastatic pancreatic cancer), this news is highly relevant to Candel Therapeutics and its investors. The importance is rated high due to the potential implications for the company's product pipeline and future revenue streams. Confidence in this analysis is moderately high, based on typical market reactions to similar news in the biotech sector.